Strategy News - Pharmaceutical Executive


Strategy News
The art and science of running a successful pharmaceutical company.

Roche Shifts Execs in Anticipation of Departures

September 9, 2009

With the pending retirement of three senior-level executives, Roche announced a new corporate executive team to bridge the personnel gap while the company looks for new leaders.

Amylin Drops 200 Sales Reps

May 7, 2009

As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.

Bio Companies Low on Venture Capital Cash

May 6, 2009

As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop.

Pharma Steps Up to Help With Swine Flu

April 29, 2009

As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic.

J&J Eliminates 900 Sales Positions

April 15, 2009

In an effort to realign its sales division to reflect the current pharma environment—smaller, faster, better—Johnson & Johnson is trimming its sales force.

Post-Employment Restrictive Covenants

April 8, 2009

A company’s trade secrets and the goodwill it has developed can mean the difference between a blockbuster and a failure. Here’s what you should know and do to properly negotiate post-employment agreements.

Pfizer Begins Wyeth Integration with New Research Structure

April 8, 2009

Just two months after the purchase of Wyeth, Pfizer breaks its research division into two—one for large molecules and vaccines, and another for small molecules—with Wyeth and Pfizer execs at the helms.

Prescription Abandonment Numbers on the Rise

April 1, 2009

Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose.

Shire Joins with GSK to Promote ADHD Drug

April 1, 2009

Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.


Click here